GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taysha Gene Therapies Inc (NAS:TSHA) » Definitions » Altman Z-Score

Taysha Gene Therapies (Taysha Gene Therapies) Altman Z-Score : -2.37 (As of May. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Taysha Gene Therapies Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of -2.37 is in distress zone. This implies bankruptcy possibility in the next two years.

Taysha Gene Therapies has a Altman Z-Score of -2.37, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Taysha Gene Therapies's Altman Z-Score or its related term are showing as below:

TSHA' s Altman Z-Score Range Over the Past 10 Years
Min: -7.67   Med: -5.48   Max: -2.37
Current: -2.37

During the past 5 years, Taysha Gene Therapies's highest Altman Z-Score was -2.37. The lowest was -7.67. And the median was -5.48.


Taysha Gene Therapies Altman Z-Score Historical Data

The historical data trend for Taysha Gene Therapies's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taysha Gene Therapies Altman Z-Score Chart

Taysha Gene Therapies Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
- - - -7.67 -3.29

Taysha Gene Therapies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.67 -9.42 -12.03 -6.06 -3.29

Competitive Comparison of Taysha Gene Therapies's Altman Z-Score

For the Biotechnology subindustry, Taysha Gene Therapies's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taysha Gene Therapies's Altman Z-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Taysha Gene Therapies's Altman Z-Score falls into.



Taysha Gene Therapies Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Taysha Gene Therapies's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.6548+1.4*-2.97+3.3*-0.617+0.6*4.9148+1.0*0.0895
=-2.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $172.73 Mil.
Total Current Assets was $149.87 Mil.
Total Current Liabilities was $36.76 Mil.
Retained Earnings was $-513.01 Mil.
Pre-Tax Income was 47.741 + -117.087 + -24.598 + -17.622 = $-111.57 Mil.
Interest Expense was -0.713 + -1.471 + -1.44 + -1.374 = $-5.00 Mil.
Revenue was 3.604 + 4.746 + 2.395 + 4.706 = $15.45 Mil.
Market Cap (Today) was $480.64 Mil.
Total Liabilities was $97.79 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(149.868 - 36.756)/172.731
=0.6548

X2=Retained Earnings/Total Assets
=-513.007/172.731
=-2.97

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-111.566 - -4.998)/172.731
=-0.617

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=480.637/97.794
=4.9148

X5=Revenue/Total Assets
=15.451/172.731
=0.0895

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Taysha Gene Therapies has a Altman Z-Score of -2.37 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Taysha Gene Therapies  (NAS:TSHA) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Taysha Gene Therapies Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Taysha Gene Therapies's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Taysha Gene Therapies (Taysha Gene Therapies) Business Description

Traded in Other Exchanges
N/A
Address
3000 Pegasus Park Drive, Suite 1430, Dallas, TX, USA, 75247
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
Executives
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Alison S Long director KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kamran Alam officer: Chief Financial Officer 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
Sean P. Nolan director C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Phillip B. Donenberg director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Stalfort John A Iii director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Session R.a. Ii 10 percent owner C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Sukumar Nagendran director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Astellas Pharma Inc. 10 percent owner 2-5-1, NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-8411
Audentes Therapeutics, Inc. 10 percent owner 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108
Suyash Prasad officer: CMO and Head of R&D C/O AUDENTES THERAPEUTICS, INC., 101 MONTGOMERY ST., SUITE 2650, SAN FRANCISCO CA 94104
Laura Sepp-lorenzino director C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Kathleen Reape director C/O TAYSHA GENE THERAPIES, INC., 2280 INWOOD ROAD, DALLAS TX 75235

Taysha Gene Therapies (Taysha Gene Therapies) Headlines

From GuruFocus

Taysha Announces Pricing of Public Offering of Common Stock

By Value_Insider Value_Insider 10-27-2022